What’s Trending?

US regulators have further expanded the scope of Bristol Myers Squibb's Opdivo, approving its use for a previously treated small cell lung cancer. [...]
Mon, Aug 20, 2018
Source PharmaTimes
Cost regulators for the NHS in England and Wales have not approved funding for TiGenix and Takeda's Alofisel - the first allogeneic stem cell therapy to be approved for use across the European Union – for use in Crohn's patients. [...]
Mon, Aug 20, 2018
Source PharmaTimes
The number of children and young people being treated for Type II diabetes has leapt by around 40 percent in just four years to more than 700 cases, NHS data show. [...]
Mon, Aug 20, 2018
Source PharmaTimes
Confusion about cancer symptoms among workers could be leading to delayed diagnoses and irregular self-examinations, suggests new research by Bupa UK. [...]
Mon, Aug 20, 2018
Source PharmaTimes
Bristol-Myers Squibb may be trailing rival Merck in the non-small cell lung cancer market, but it's landed a niche of its own in the small cell arena. [...]
Fri, Aug 17, 2018
Source FiercePharma
Only days after the FDA turned away Regeneron's Eylea for a label expansion, the drugmaker has secured the approval it sought. [...]
Fri, Aug 17, 2018
Source FiercePharma
China's former FDA chief resigns from his leadership role at the new market regulatory agency over the latest vaccine scandal; Astellas buys U.K. gene therapy developer Quethera for $109 million; the FDA found quality-control problems at Zhejiang Huahai Pharmaceutical a year ahead of the valsartan recall. [...]
Fri, Aug 17, 2018
Source FiercePharma
Novo Nordisk
Ziylo and Novo Nordisk A/S today announced that Novo Nordisk has acquired all of the shares of Ziylo, a University of Bristol spin-out company based at Unit DX science incubator in Bristol, UK. Ziylo has been pioneering the use of its platform technology - synthetic glucose binding molecules - for [...]
Fri, Aug 17, 2018
Source WorldPharmaNews
Eisai and Merck's fast-growing Lenvima's got a brand new market—and Bayer's Nexavar has some company in the previously untreated liver cancer arena. [...]
Thu, Aug 16, 2018
Source FiercePharma
Tuberculosis is one of the top 10 causes of death worldwide. Nearly 2 million people die every year from this infectious disease, and an estimated 2 billion people are chronically infected. The only vaccine, developed almost 100 years ago, offers limited protection and patients are becoming increasingly resistant to available [...]
Thu, Aug 16, 2018
Source WorldPharmaNews
Merck
Merck, the vibrant science and technology company, today announced that the Australian Patent Office has allowed the company's patent application for the use of paired CRISPR nickases. Paired nickases represent a significant step in increasing safety by driving specificity through a highly flexible and efficient approach to reduce off-target effects. [...]
Wed, Aug 15, 2018
Source WorldPharmaNews
For the first time, Mount Sinai researchers have identified a way to make large numbers of immune cells that can help prevent cancer reoccurrence, according to a study published in August in Cell Reports. The researchers discovered a way to grow the immune cells, called dendritic cells, at large scale [...]
Tue, Aug 14, 2018
Source WorldPharmaNews
Sponsors submitting pediatric study plans should consider whether a product affects adults and children similarly when choosing an approach, the FDA says. [...]
Fri, Jan 16, 2015
Source FDANews